eCIO Initiates Stake in Eli Lilly and Company (LLY) with 886 Shares

Eli Lilly and Company (NYSE:LLY) is among the high growth mega cap stocks you can buy and hold for the next 3 years. During the first quarter, eCIO Inc. acquired a new position in Eli Lilly and Company (NYSE:LLY) through the purchase of 886 shares. According to the latest disclosure with the SEC, the firm’s investment in the company is valued at approximately $732,000.

At a time when being lean is the new luxury, Eli Lilly and Company (NYSE:LLY) is doing what it does best. The company is focusing on obesity and type 2 diabetes treatment markets at a speed only a few can match. While the tirzepatide franchise captures the GLP-1 market, the company’s orforglipron, an experimental drug, continues to be more effective than the competitor’s Rybelsus.

The comparative statistics are a testament to the company’s strong market standing, with its 3-year and 5-year returns surpassing the market’s returns by 78.37% and 332.72%, respectively. With confidence around the oral GLP-1 segment, entering a pivotal stage of growth in 2026 onwards, we can only expect Eli Lilly and Company (NYSE:LLY) to outperform.

Eli Lilly and Company (NYSE:LLY) is an Indiana-based company that specializes in human pharmaceuticals. Founded in 1876, the company is committed to making life better for people all over the globe.

While we acknowledge the potential of LLY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None.